A Phase 3 trial of a combination therapy for metastatic melanoma has been stopped early because an interim analysis showed an overall survival benefit for the treatment group compared with the control, according to the developer GlaxoSmithKline Plc. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News Clinical Research
